SpringWorks Therapeutics, Inc.
NASDAQ:SWTX
Overview | Financials
Company Name | SpringWorks Therapeutics, Inc. |
Symbol | SWTX |
Currency | USD |
Price | 33.09 |
Market Cap | 2,457,693,570 |
Dividend Yield | 0% |
52-week-range | 18 - 53.92 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Saqib Islam J.D. |
Website | https://www.springworkstx.com |
An error occurred while fetching data.
About SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD